In this interview from the ASRS 2013 Annual Meeting, Dr. Barry Kupperman discusses a wide-ranging meta-analysis conducted on the systemic safety effects of ranibizumab injected monthly for all applicable diseases: age-related macular degeneration (AMD), retinal vein occlusion (RVO), and diabetic macular edema (DME). The meta-analysis examined all the major clinical trials for the intravitreal injection of ranibizumab and found there was no increased systemic risk in either the AMD or RVO patient group. While there was numerical evidence that risk of serious adverse events such as stroke and wound complications was increased in the DME patient group, the difference was not statistcally significant. Dr. Kupperman also discusses the safety differences between the use of 0.3-mg and 0.5-mg dosage, and how clinicans might balance efficacy of intravitreal injections with the risk associated with a long-term monthly injection protocol.